Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells

Leukemia and Lymphoma

Volumn 33, Issue 5-6, 1999, Pages 485-497

  Chiodini, Barbara ^a   Bassan, Renato ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Cyclosporin A; Idarubucin; Leukemia; Multidrug resistance

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; DRUG METABOLITE; GLYCOPROTEIN P; IDARUBICIN; LIPOCORTIN 5;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG ACCUMULATION; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0032928916     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909058453     Document Type: Article

References (34)

1. Richardson, D. S., Johnson, S. A. (1997). Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev, 11, 201-223.
2. Hannun, Y. A. (1997). Apoptosis and the dilemma of cancer chemotherapy. Blood, 89, 1845-1853.
3. Speth, P. A. J., Minderman, H. and Haanen, C. (1989). Idarubicin V daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol, 16 (Suppl 2), 2-9.
4. Reid, J. M., Pendergrass, T. W., Krailo, M. D., Hammond, G. D. and Ames, M. M. (1990). Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients. A Childrens Cancer Study Group report. Cancer Res, 50, 6525-6528.
5. Ames, M. A., Spreafico, F. (1992). Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia, 6 (Suppl 1), 70-75.
6. Zanette, L., Zucchetti, M., Freshi, A., Erranti, D., Tirelli, U. and D'Incalci, M. (1990). Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol, 25, 445-448.
7. Johnson, S. A., Richardson, D. S. (1998). Anthracyclines in haematology: pharmacokinetics and clinical studies. Blood Rev, 12, 52-71.
8. Muller, C., Chatelut, E., Gualano, V., De Forni, M., Huguet, F., Attal, M., Canal, P., Laurent, G. (1993). Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol, 32, 379-384.
9. Bassan, R., Chiodini, B., Zucchetti, M., Lerede, T., Cornelli, P. E., Cortelazzo, S. and Barbui, T. (1998). Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. Haematologica, 83, 27-33.
10. Wheatley, K. (1995). Meta-analysis of randomized trials of idarubicin (IDAR) or mitozantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukemia (AML) (Abstrat). Blood, 86 (Suppl 1), 434a.
11. Bassan, R. and Barbui, T. (1995). Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica, 80, 82-90.
12. Bassan, R., Lerede, T., Rambaldi, A., Di Bona, E., Rossi, G., Pogliani, E., Lambertenghi-Deliliers, G., Porcellini, A., Fabris, P. and Barbui, T. (1996). The role of anthracyclines in adult acute lymphoblastic leukemia. Leukemia, 10 (Suppl 2), S58-S61.
13. Germann, U. A. (1996). P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer, 32A, 927-944.
14. te Boekhorst, P. A. W., Lowenberg, B., van Kapel, J., Nooter, K. and Sonneveld, P. (1995). Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia, 9, 1025-1031.
15. Del Poeta, G., Stasi, R., Aronica, G., Venditti, A., Cox, M. C., Bruno, A., Buccisano, F., Masi, M., Tribalto, M., Amadori, S. and Papa, G. (1996). Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood, 87, 1997-2004.
16. Berman, E. and McBride, M. (1992). Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood, 79, 3267-3273.
17. Ross, D., Tong, Y. and Cornblatt, B. (1993). Idarubicin (IDA) is less vulnerable to transport-mediated multidrug resistance (MDR) than its metabolite idarubicinol (IDAol) or daunorubicin (DNR) (Abstract). Blood, 82 (Suppl 1), 257a, 1015.
18. Kuffel, M. J., Reid, J. M. and Ames, M. M. (1992). Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol, 30, 51-57.
19. Michieli, M., Michelutti, A., Damiani, D., Pipan, C., Raspadori, D., Lauria, F. and Baccarani, M. (1993). A comparative analyis of sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leuk Lymphoma, 9, 255-264.
20. List, A. F., Speier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, B. and Dalton, W. (1993). Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol, 11, 1652-1660.
21. List, A. F. (1996). The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia, 10 (Suppl 2), S46-S51.
22. Hegewisch-Becker, S. (1996). MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia, 10 (Suppl 3), S32-S38.
23. Kornblau, S. M., Estey, E., Madden, T., Tran, H. T., Zhao, S., Consoli, U., Snell, V., Sanchez-Williams, G., Kantarjian, H., Keating, M., Newman, R. A. and Andreeff, M. (1997). Phase 1 study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol, 15, 1796-1802.
24. - cases. Blood, 86, 2329-2542.
25. Bassan, R., Chiodini, B., Lerede, T., Torri, V., Rambaldi, A. and Barbui, T. (1997). The role of idarubicin in adult acute lymphoblastic leukemia: from drug resistance studies to clinical application. Leukemia Lymphoma, 26 (Suppl 1), 89-97.
26. Koopman, G., Reutelingsperger, C. P. M., Kuijten, G. A. M., Keehnen, R. M. J., Pals, S. T. and van Oers, M. H. J. (1994). Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 84, 1415-1420.
27. Geyp, M., Ireland, C. M. and Pittman, S. M. (1996). Resistance to apoptotic cell death in a drug resistant T cell leukemia cell line. Leukemia, 10, 447-455.
28. Kokenberg, E., Sonneveld, P., Delwel, R., Sizoo, W., Hagenbeek, A. and Löwenberg, B. (1988). In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia, 2, 511-517.
29. Pieters, R., Loonen, A. H., Huismans, D. R., Broekema, G. J., Dirven, M. W. J., Heyenbrok, M. W., Hählen, K., and Veerman, A. J. P. (1990). In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood, 76, 2327-2336.
30. Damiani, D., Michieli, M., Michelutti, A., Pea, F., Baraldo, M., Fanin, R., Russo, D., Furlanut, M. and Baccarani, M. (1995). P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases. Leukemia, 9, 1792-1795.
31. Grey, M. R., Burgess, R., Fisher, A., Liu Yin, J. A. (1996). Idarubicin is superior to daunorubicin when used with the multidrug resistance modifier, PSC 833, in acute myeloid leukemia (Abstract). Br J Haematol, 93, 64 (Suppl 1), 245.
32. Minderman, H., Linssen, P., van der Lely, N., Wessels, J., Boezeman, J., de Witte, T., Haanen, C. (1994). Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia, 8, 382-387.
33. Ito, C., Ribeiro, R. C., Behm, F. G., Raimondi, S. C., Pui, C.-H. and Campana, D. (1998). Cyclosporine A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood, 91, 1001-1007.
34. Ross, D. D., Wooten, P. J., Tong, Y., Cornblatt, B., Levy, C., Sridhara, R., Lee, E. J. and Schiffer, C., A. (1994). Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia by cyclosporin A and cremophor EL. Blood, 83, 1337-1347.